Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for RA with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.  For more information, visit www.rigel.com

About AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

This press release contains "forward-looking" statements, including, without limitation, statements related to the further development of, and the therapeutic and commercial potential of, fostamatinib, partnered with AstraZeneca, the results of the ongoing OSKIRA-2 and OSKIRA-3 Phase 3 studies and the timing of completion of those studies, and the timing for potential regulatory filings and publications of clinical data. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inheren
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... ON , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics ... pharmaceutical company with a focus on Omega-3 therapies for ... 25, 2015 it issued 763,752 common shares of the ... of interest for the period of December 5 th ... its outstanding Convertible Notes that is due on or ...
(Date:3/26/2015)... "Whether it,s our family, our friends, all ... In a single sentence, Dr. Anthony Coyle , ... Centers for Therapeutic Innovation (CTI), sums up ... America,s biopharmaceutical companies. CTI,s unique model ... foundations and the National Institutes of Health (NIH) to ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... International, a leading Clinical Research Organization, will host an ... development on 24 August 2010 at 11:30 am (EDT). ... Scientific Affairs unit, will be the presenter. ... the expensive failures that pharmaceutical companies experience during late-stage ...
... Bulletin Board: WGBS ), a leading developer of ... three and six months ended June 30, 2010.   ... 2010 grew to $432,000 compared to $69,000 for the second ... ended June 30, 2010 grew to $822,000 compared to $111,000 ...
Cached Medicine Technology:PRA International Hosts Audio Conference on CV Drug Development 2WaferGen Reports Second Quarter 2010 Financial Results 2WaferGen Reports Second Quarter 2010 Financial Results 3WaferGen Reports Second Quarter 2010 Financial Results 4WaferGen Reports Second Quarter 2010 Financial Results 5WaferGen Reports Second Quarter 2010 Financial Results 6WaferGen Reports Second Quarter 2010 Financial Results 7
(Date:3/28/2015)... 2015 Rocket Pure , a manufacturer ... release of their new natural sunscreen. They are offering ... Both options come with a bonus lip balm sunscreen. ... on Amazon. Click to see the natural sunscreen ... natural sunscreen is made with non-nano zinc oxide and provides ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Delaying rotator ... be necessary, according to research presented today at the ... Specialty Day. , “Our study compared results for 170 ... underwent an additional glenohumeral joint capsule release procedure to ... Murrell MD, PhD, lead author from St. George Hospital ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... have said that sleep would probably help the human brain ... facts.// ,It was reported that previous studies had ... steps of learning to tap numeric sequences on a keyboard. ... declarative memory like those used for recalling the facts for ...
... (MIMS) is planning to launch a chain of satellite hospitals ... of non-resident Indian (NRI) doctors residing in Gulf Cooperation Council ... Kottakal in Malappuram district of the state for the purpose, ... ,MIMS chairman Azad Moopen told the newspaper that the ...
... Zealand Food Safety Authority (NZFSA) has warned people against ... bags are clearly labelled as requiring to be cooked ... is known to sometimes carry norovirus, which causes a ... Korean oysters are packed frozen in 1kg bags and ...
... at the Institute Of Cancer Research have discovered a new ... disease.// ,It is found that if a person ... diagnosed with breast cancer doubles. This would serve as a ... of cancer and thereby help treat and prevent the disease. ...
... differently in the same organs of males and females ... sheds light on why the same disease often strikes ... respond differently to the same drug. ,"We ... vary in their relationship to different diseases," explained Xia ...
... begin before the age of 14 years are not only ... from alcohol until they're 21//, but they also tend to ... with alcohol throughout their lives. ,The study's lead ... of Public Health's Youth Alcohol Prevention Centre said that while ...
Cached Medicine News:Health News:Sleep Essential For A Strong Memory 2Health News:Same Genes Act Differently in Males and Females 2Health News:Same Genes Act Differently in Males and Females 3Health News:Alcoholism & Dependence Seen More Commonly In Early Alcohol Drinkers 2
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
... The easy way to order tips. Each ... tips)except for D10mL, which contains 200 tips (4 ... re-sealable Bulk Packs of 200 tips per pack. ... which can easily be opened for quick access ...
Conducting disposable tips....
Medicine Products: